

Product datasheet for TR320078

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Bcl2 Binding component 3 (BBC3) Human shRNA Plasmid Kit (Locus ID 27113)

Product data:

Product Type: shRNA Plasmids

Product Name: Bcl2 Binding component 3 (BBC3) Human shRNA Plasmid Kit (Locus ID 27113)

Locus ID:

JFY-1; JFY1; PUMA Synonyms:

Vector: pRS (TR20003)

E. coli Selection: Ampicillin Mammalian Cell

Selection:

Puromycin

Format: Retroviral plasmids

Components: BBC3 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID =

27113). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

NM 001127240, NM 001127241, NM 001127242, NM 014417, NM 014417.1, NM 014417.2, RefSeq:

> NM 014417.3, NM 014417.4, NM 001127242.1, NM 001127242.2, NM 001127241.1, NM 001127241.2, NM 001127240.1, NM 001127240.2, BC136481, NM 001127240.3,

NM 014417.5, NM 001127242.3, NM 001127241.3

UniProt ID: Q9BXH1

Summary: This gene encodes a member of the BCL-2 family of proteins. This family member belongs to

> the BH3-only pro-apoptotic subclass. The protein cooperates with direct activator proteins to induce mitochondrial outer membrane permeabilization and apoptosis. It can bind to antiapoptotic Bcl-2 family members to induce mitochondrial dysfunction and caspase activation. Because of its pro-apoptotic role, this gene is a potential drug target for cancer therapy and for tissue injury. Alternative splicing results in multiple transcript variants. [provided by

RefSeq, Dec 2011]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

> be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).